Gregory S Schultz

US Patent:

6379667, Apr 30, 2002

Filed:

Aug 3, 1999

Appl. No.:

09/368307

Inventors:

Peng Tee Khaw - London, GB
Gregory S. Schultz - Gainesville FL

Assignee:

University of Florida Research Foundation - Gainesville FL
Moorfields Eye Hospital National Health Service Trust - London

International Classification:

A61K 39395

US Classification:

4241461, 4241411, 514575

Abstract:

The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

US Patent:

6713074, Mar 30, 2004

Filed:

Jun 29, 2001

Appl. No.:

09/896566

Inventors:

David S. Lerner - Boca Raton FL
Gregory Schultz - Gainesville FL

Assignee:

Quick Med Technologies Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 700

US Classification:

424401, 424 59, 514 23, 514 24, 514 25, 514 26, 514 33, 514182

Abstract:

The cosmetic topical formulation of this invention is directed toward diminishing skin wrinkling, fine line, improving skin tone, and combinations thereof. Preferably, the topical formulation contains a matrix metalloproteinase inhibitor, MMPI, and advantageously includes a natural estrogen, e. g. , a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal preparations), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMP inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethinyl estradiol and clomiphine citrate. The cosmetic topical formulation is safe and effective diminishing wrinkling, and improving skin tone. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking.

US Patent:

6759432, Jul 6, 2004

Filed:

Apr 29, 2002

Appl. No.:

10/135934

Inventors:

Peng Tee Khaw - London, GB
Gregory S. Schultz - Gainesville FL

Assignee:

University of Florida Research Foundation - Gainesville FL
Moorfields Eye Hospital National Health Service Trust - London
The Institute of Ophthalmology - London

International Classification:

A61K 3119

US Classification:

514575

Abstract:

The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.

US Patent:

7045673, May 16, 2006

Filed:

Dec 8, 1999

Appl. No.:

09/857906

Inventors:

Christopher D. Batich - Gainesville FL, US
Bruce A Mast - Gainesville FL, US
Gregory Schultz - Gainesville FL, US
Gerald M. Olderman - New Bedford MA, US
David S. Lerner - Boca Raton FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61F 13/00

US Classification:

602 48, 602 42, 602 43, 424443, 424447

Abstract:

Absorbent dressings, including highly-absorbent dressings having antimicrobial polymer attached thereto via non-siloxane bonds are disclosed. Bandages (i. e. wound dressing), sanitary napkins and the like are useful applications for the intrinsically bactericidal absorbent dressings whose method of manufacture and use are disclosed and claimed.

US Patent:

7335763, Feb 26, 2008

Filed:

Mar 24, 2004

Appl. No.:

10/808042

Inventors:

Alfred Samuel Lewin - Gainesville FL, US
David Clair Bloom - Gainesville FL, US
Gregory Scott Schultz - Gainesville FL, US
Sonal Sanjeen Tuli - Gainesville FL, US
Jia Liu - Gainesville FL, US

Assignee:

University of Florida Research Foundation, Inc. - Gainsville FL

International Classification:

C07H 21/04

US Classification:

536 245

Abstract:

Hammerhead ribozymes that target components critical to HSV replication (ICP4, UL20, UL30, and UL54) were synthesized and shown to efficiently cleave target RNA encoding a portion of these components in in vitro assays. Several cloned cell lines stably expressing these ribozymes were established. HSV-mediated plaque formation was dramatically reduced in cells stably transfected with an anti-HSV ribozyme compared to non-transfected cells.

US Patent:

7462602, Dec 9, 2008

Filed:

Apr 30, 2004

Appl. No.:

10/836670

Inventors:

Gregory S. Schultz - Gainesville FL, US
Alfred S. Lewin - Gainesville FL, US
Timothy D. Blalock - Boston MA, US

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A01N 43/04
C12Q 1/68
C12Q 19/34
C07H 21/02
C07H 21/04

US Classification:

514 44, 435 6, 435 911, 435 9131, 4353201, 435455, 536 231, 536 245

Abstract:

Methods and compositions for treating scarring conditions associated with increased expression of connective tissue growth factor (CTGF). Aspects of the invention include ribozymes that cleave mRNA targets required for CTGF expression, cells containing anti-CTGF ribozymes and vectored anti-CTGF ribozymes suitable for delivery to cellular targets capable of CTGF expression.

US Patent:

7709694, May 4, 2010

Filed:

Sep 28, 2001

Appl. No.:

09/965740

Inventors:

Christopher D. Batich - Gainesville FL, US
Gregory Schultz - Gainesville FL, US
Bruce A. Mast - Gainesville FL, US
Gerald M. Olderman - New Bedford MA, US
David S. Lerner - Boca Raton FL, US
William Toreki - Gainesville FL, US

Assignee:

Quick-Med Technologies, Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61F 13/00

US Classification:

604360, 602 48, 427 231

Abstract:

This invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymer chains and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial effect.

US Patent:

7838659, Nov 23, 2010

Filed:

Feb 25, 2008

Appl. No.:

12/036365

Inventors:

Alfred S. Lewin - Gainesville FL, US
David C. Bloom - Gainesville FL, US
Gregory S. Schultz - Gainesville FL, US
Sonal Sanjeev Tuli - Gainesville FL, US
Jia Liu - Gainesville FL, US

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

C07H 21/04

US Classification:

536 245

Abstract:

Hammerhead ribozymes that target components critical to HSV replication (ICP4, U20, U30, and U54) were synthesized and shown to efficiently cleave target RNA encoding a portion of these components in in vitro assays. Several cloned cell lines stably expressing these ribozymes were established. HSV-mediated plaque formation was dramatically reduced in cells stably transfected with an anti-HSV ribozyme compared to non-transfected cells.

Address:

10622 Irvin Pne Dr, Louisville, KY 40229

VIN:

WVWAR71K07W125106

Make:

VOLKSWAGEN

Model:

RABBIT

Year:

2007